Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huo Su

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Foods (Basel, Switzerland)|February 26, 2025
Gut Microbiota and Neurotransmitter Regulation: Functional Effects of Four Traditional Chinese Fermented Soybean (Sojae Semen Praeparatum)Lin Zhang, Huo Su, Siqi Wang, et al.
Vaccines|May 7, 2025
Fc-Modified Antibody in Hospitalized Severe COVID-19 PatientsFelipe Dal-Pizzol, Suzana Margareth Lobo, Christopher Lucasti, et al.
Biomaterials Science|November 8, 2021
Recent advancements in peripheral nerve-specific fluorescent compoundsBo Wei, Huo Su, Pei Chen, et al.
Chemistry & Biodiversity|December 19, 2009
Chemical constituents of the plants from genus JatrophaXi-Ping Zhang, Man-Li Zhang, Xiao-Huo Su, et al.
Journal of Clinical and Translational Hepatology|August 14, 2023
Current Status and Analysis of Machine Learning in Hepatocellular CarcinomaSijia Feng, Jianhua Wang, Liheng Wang, et al.
Vaccines|October 26, 2024
Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated AdultsSuad Hannawi, Alaa Abuquta, Linda Saf Eldin, et al.
Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Foods (Basel, Switzerland)|February 26, 2025
Gut Microbiota and Neurotransmitter Regulation: Functional Effects of Four Traditional Chinese Fermented Soybean (Sojae Semen Praeparatum)Lin Zhang, Huo Su, Siqi Wang, et al.
Vaccines|May 7, 2025
Fc-Modified Antibody in Hospitalized Severe COVID-19 PatientsFelipe Dal-Pizzol, Suzana Margareth Lobo, Christopher Lucasti, et al.
Biomaterials Science|November 8, 2021
Recent advancements in peripheral nerve-specific fluorescent compoundsBo Wei, Huo Su, Pei Chen, et al.
Chemistry & Biodiversity|December 19, 2009
Chemical constituents of the plants from genus JatrophaXi-Ping Zhang, Man-Li Zhang, Xiao-Huo Su, et al.
Journal of Clinical and Translational Hepatology|August 14, 2023
Current Status and Analysis of Machine Learning in Hepatocellular CarcinomaSijia Feng, Jianhua Wang, Liheng Wang, et al.
Vaccines|October 26, 2024
Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated AdultsSuad Hannawi, Alaa Abuquta, Linda Saf Eldin, et al.
Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Pageof 1